Meetings and Conferences · Tagungen und Kongresse
Isabell Witzel, Manfred Johannsen(Charité - Universitätsmedizin Berlin), Anastasios Mahairas, Keunyoung Kim, Jonas Busch(Charité - Universitätsmedizin Berlin), Arnold Ganser(Medizinische Hochschule Hannover), Kyoungjune Pak(Pusan National University Hospital), Antje Johannsen(Charité - Universitätsmedizin Berlin), Carlo Buonerba(CTO Andrea Alesini), Daniel C. Christoph(Evangelisches Krankenhaus Königin Elisabeth Herzberge), Julia Zeitz, Nadia Harbeck(Breast Center), Annette Schmitt‐Graeff, Martin Schüler(German Cancer Research Center), Eliahu Golomb, Tal Grenader(Shaare Zedek Medical Center), Christoph Pöttgen(University of Duisburg-Essen), In Joo Kim, Maike Ihnen, Lukas Wittkowski, Thomas Gauler, F. Jänicke, Laura Debatin, Kathy Keyvani(Essen University Hospital), Pilar Garrido(Hospital Universitario Ramón y Cajal), Seong‐Jang Kim(Pusan National University Yangsan Hospital), Giuseppe Di Lorenzo(Saint Camillus International University of Health and Medical Sciences), Hendrik Veelken(University of Freiburg), Martin Fenner(PEN American Center), Wilfried Eberhardt(National Center for Tumor Diseases), Christoph Seidel(Medizinische Hochschule Hannover), Eva Johanna Kantelhardt(Martin Luther University Halle-Wittenberg), Federico Longo(Instituto Cajal), Christoph Reuter(Department of Space), Binay Kumar Shah(Shanghai Tenth People's Hospital), Alejandro Riquelme, M.E. Olmedo(Instituto Ramón y Cajal de Investigación Sanitaria), Vasileios Smyrniotis, Steffen Weikert(St. Hedwig-Krankenhaus), Jörg Stattaus, George H. Sakorafas, Volkmar Müller, Mercedes Rodríguez, Bum Soo Kim, Tara Shah(The University of Texas MD Anderson Cancer Center), Viktor Grünwald(Deutsche Schmerzgesellschaft), Karin Milde‐Langosch(Universität Hamburg), Anthony Goldberg
Cited by 0
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k